Magenta therapeutics reports third quarter financial results and recent program highlights

– new clinical results from ongoing mgta-117 phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has progressed into the third dose escalation cohort; oral presentation of clinical data will be given at the 2022 american society of hematology (ash) meeting in december 2022 –
DNTH Ratings Summary
DNTH Quant Ranking